Limits...
A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study.

Benichou AC, Armanet M, Bussière A, Chevreau N, Cardot JM, Tétard J - Food Sci Nutr (2014)

Bottom Line: At all postchallenge time points, the active group had higher PNIF values compared to the placebo group, indicating that the active product was associated with fewer symptoms and reduced intensity of these symptoms.The active product resulted also in statistically significant improvements of most of the subjects' perceived feelings of well-being based on VAS scores.In conclusion, the dietary supplement consisting of proprietary blend made of quail eggs provides fast and efficient relief of allergic rhinitis symptoms caused by the most common outdoor and indoor allergens, without adverse events.

View Article: PubMed Central - PubMed

Affiliation: Stragen Services SAS Lyon, France.

ABSTRACT
Occasional rhinitis symptoms caused by exposure to pollution or allergens is a growing concern. Based first on empirical observation of a lesser occurrence of allergies in quail farmers and then scientific works on ovomucoids properties, we developed a dietary supplement for the relief of such occasional rhinitis symptoms. The objective of the study was to determine whether one acute oral dose of the study product attenuates nasal provocation and other allergy-related symptoms after exposure to a standardized allergenic challenge as compared to placebo. Healthy subjects were recruited to participate in a randomized, double-blind, two-arm crossover, placebo-controlled, clinical trial. One acute dose of either the active study product (proprietary blend of quail egg) or placebo was given concomitantly to the standardized allergenic challenge. The primary endpoint was peak nasal inspiratory flow (PNIF) measurement and the secondary endpoints were subjects' perceived feelings of well-being based on Visual Analog Scale (VAS) scores for allergy-related symptoms, as well as immunoglobulin E count. Forty-three healthy subjects were enrolled and evaluable in a per protocol analysis. A gradual increase in PNIF from nadir up to Time 120 reflected the normal, gradual recovery from nasal obstruction induced by allergenic challenge for both the active and the placebo groups. At all postchallenge time points, the active group had higher PNIF values compared to the placebo group, indicating that the active product was associated with fewer symptoms and reduced intensity of these symptoms. The active product resulted also in statistically significant improvements of most of the subjects' perceived feelings of well-being based on VAS scores. No adverse events occurred during the study. In conclusion, the dietary supplement consisting of proprietary blend made of quail eggs provides fast and efficient relief of allergic rhinitis symptoms caused by the most common outdoor and indoor allergens, without adverse events.

No MeSH data available.


Related in: MedlinePlus

Average peak nasal inspiratory flow (PNIF) variation from baseline: (PNIF(t) − PNIF (Pre)/PNIF (Pre) × 100) for active and placebo groups according to time in minutes forn = 39 (per protocol subset). *Significant difference at time 15 and 60 min,P = 0.0271 and 0.0287, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4256569&req=5

fig05: Average peak nasal inspiratory flow (PNIF) variation from baseline: (PNIF(t) − PNIF (Pre)/PNIF (Pre) × 100) for active and placebo groups according to time in minutes forn = 39 (per protocol subset). *Significant difference at time 15 and 60 min,P = 0.0271 and 0.0287, respectively.

Mentions: From the PP analysis, a significant difference occurred in PNIF for the 0–120 min postchallenge period (P = 0.0107). The overall means were 121.7 versus 117.6 for active and placebo, respectively. The multiple post hoc comparison showed a trend toward significance located at Time 15 min (P = 0.0620). The nonparametric approach resulted in a significant difference for the 0–120 min time period (P = 0.0410). When considering the data time by time, a significant difference occurred at 15 min (P = 0.0235). A secondary analysis was performed on the variation versus baseline (the progression vs. baseline corrected parameters) for all points (PNIF(t) − PNIF (Pre))/PNIF (Pre) × 100 (Table2 and Fig.4). On the progression versus baseline corrected parameters, a significant overall difference was observed (P = 0.0051) with a trend toward significance at Time 15 min (P = 0.0602). Nonparametric analysis was performed and showed similar results. As presented in Figure4, when considering differences in PNIF value versus baseline expressed as a percentage of baseline, an improvement of 27.7% was observed at 15 min postchallenge in subjects taking the active product versus placebo, and an improvement of 23.8% for the active product at Time 90 versus placebo. Similar analyses were performed with the PP subset ofn = 39. For PNIF values, consumption of the active product resulted in significantly improved breathing through the nose compared to placebo (P = 0.0035). The inference post hoc comparison shows a trend toward significance at Time 15 min (P = 0.0556). When considering the data time by time, a significant difference occurred at 15 min (P = 0.0290). Nonparametric analysis showed similar results. On the progression versus baseline corrected parameters an overall difference was observed (P = 0.0002) with statistically significant differences at Time 15 and 60 min (P = 0.0271 and 0.0287, respectively) and a trend toward significance at Time 30 (P = 0.0533). When considering the data time by time, the difference was mainly located at 15 min (P = 0.0261) and 60 min (P = 0.0582). Nonparametric analysis was performed and showed similar results. (Table2 and Fig.5). When considering differences in PNIF value versus baseline expressed as a percent of baseline, at Time 15 min postchallenge, administration of the active product resulted in an improvement of 31.8% compared to placebo. There was also an improvement of 36.5% for the active product versus placebo at Time 90.


A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study.

Benichou AC, Armanet M, Bussière A, Chevreau N, Cardot JM, Tétard J - Food Sci Nutr (2014)

Average peak nasal inspiratory flow (PNIF) variation from baseline: (PNIF(t) − PNIF (Pre)/PNIF (Pre) × 100) for active and placebo groups according to time in minutes forn = 39 (per protocol subset). *Significant difference at time 15 and 60 min,P = 0.0271 and 0.0287, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4256569&req=5

fig05: Average peak nasal inspiratory flow (PNIF) variation from baseline: (PNIF(t) − PNIF (Pre)/PNIF (Pre) × 100) for active and placebo groups according to time in minutes forn = 39 (per protocol subset). *Significant difference at time 15 and 60 min,P = 0.0271 and 0.0287, respectively.
Mentions: From the PP analysis, a significant difference occurred in PNIF for the 0–120 min postchallenge period (P = 0.0107). The overall means were 121.7 versus 117.6 for active and placebo, respectively. The multiple post hoc comparison showed a trend toward significance located at Time 15 min (P = 0.0620). The nonparametric approach resulted in a significant difference for the 0–120 min time period (P = 0.0410). When considering the data time by time, a significant difference occurred at 15 min (P = 0.0235). A secondary analysis was performed on the variation versus baseline (the progression vs. baseline corrected parameters) for all points (PNIF(t) − PNIF (Pre))/PNIF (Pre) × 100 (Table2 and Fig.4). On the progression versus baseline corrected parameters, a significant overall difference was observed (P = 0.0051) with a trend toward significance at Time 15 min (P = 0.0602). Nonparametric analysis was performed and showed similar results. As presented in Figure4, when considering differences in PNIF value versus baseline expressed as a percentage of baseline, an improvement of 27.7% was observed at 15 min postchallenge in subjects taking the active product versus placebo, and an improvement of 23.8% for the active product at Time 90 versus placebo. Similar analyses were performed with the PP subset ofn = 39. For PNIF values, consumption of the active product resulted in significantly improved breathing through the nose compared to placebo (P = 0.0035). The inference post hoc comparison shows a trend toward significance at Time 15 min (P = 0.0556). When considering the data time by time, a significant difference occurred at 15 min (P = 0.0290). Nonparametric analysis showed similar results. On the progression versus baseline corrected parameters an overall difference was observed (P = 0.0002) with statistically significant differences at Time 15 and 60 min (P = 0.0271 and 0.0287, respectively) and a trend toward significance at Time 30 (P = 0.0533). When considering the data time by time, the difference was mainly located at 15 min (P = 0.0261) and 60 min (P = 0.0582). Nonparametric analysis was performed and showed similar results. (Table2 and Fig.5). When considering differences in PNIF value versus baseline expressed as a percent of baseline, at Time 15 min postchallenge, administration of the active product resulted in an improvement of 31.8% compared to placebo. There was also an improvement of 36.5% for the active product versus placebo at Time 90.

Bottom Line: At all postchallenge time points, the active group had higher PNIF values compared to the placebo group, indicating that the active product was associated with fewer symptoms and reduced intensity of these symptoms.The active product resulted also in statistically significant improvements of most of the subjects' perceived feelings of well-being based on VAS scores.In conclusion, the dietary supplement consisting of proprietary blend made of quail eggs provides fast and efficient relief of allergic rhinitis symptoms caused by the most common outdoor and indoor allergens, without adverse events.

View Article: PubMed Central - PubMed

Affiliation: Stragen Services SAS Lyon, France.

ABSTRACT
Occasional rhinitis symptoms caused by exposure to pollution or allergens is a growing concern. Based first on empirical observation of a lesser occurrence of allergies in quail farmers and then scientific works on ovomucoids properties, we developed a dietary supplement for the relief of such occasional rhinitis symptoms. The objective of the study was to determine whether one acute oral dose of the study product attenuates nasal provocation and other allergy-related symptoms after exposure to a standardized allergenic challenge as compared to placebo. Healthy subjects were recruited to participate in a randomized, double-blind, two-arm crossover, placebo-controlled, clinical trial. One acute dose of either the active study product (proprietary blend of quail egg) or placebo was given concomitantly to the standardized allergenic challenge. The primary endpoint was peak nasal inspiratory flow (PNIF) measurement and the secondary endpoints were subjects' perceived feelings of well-being based on Visual Analog Scale (VAS) scores for allergy-related symptoms, as well as immunoglobulin E count. Forty-three healthy subjects were enrolled and evaluable in a per protocol analysis. A gradual increase in PNIF from nadir up to Time 120 reflected the normal, gradual recovery from nasal obstruction induced by allergenic challenge for both the active and the placebo groups. At all postchallenge time points, the active group had higher PNIF values compared to the placebo group, indicating that the active product was associated with fewer symptoms and reduced intensity of these symptoms. The active product resulted also in statistically significant improvements of most of the subjects' perceived feelings of well-being based on VAS scores. No adverse events occurred during the study. In conclusion, the dietary supplement consisting of proprietary blend made of quail eggs provides fast and efficient relief of allergic rhinitis symptoms caused by the most common outdoor and indoor allergens, without adverse events.

No MeSH data available.


Related in: MedlinePlus